title: Potential immunosuppressive therapeutics to target small vessel vasculitis of the kidney.
abstract: Small vessel vasculitis of the kidney is an inflammatory disorder that results in glomerulonephritis. Current treatment regimes have proved effective, with patient survival rates of 80% at five years. Of the 20% that die, a significant number of deaths are due to the side effects of therapies, and immunosuppression. A more tailored approach is required that targets the cells involved rather than generally restraining the immune system. This can only be achieved by increasing our knowledge of disease pathogenesis.
authors.affiliation: Renal Immunobiology, Division of Immunity and Infection, The Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. J.M.Williams.MED@bham.ac.uk
authors.forename: Julie M
authors.initials: JM
authors.lastname: Williams
mesh_terms: D000818:Animals; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D002448:Cell Adhesion / Q000187:drug effects; D016503:Drug Delivery Systems; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000378:metabolism; D007674:Kidney Diseases / Q000188:drug therapy* / Q000276:immunology; D018375:Neutrophil Activation / Q000187:drug effects; D020556:Neutrophil Infiltration / Q000187:drug effects; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D010587:Phagocytosis / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D014657:Vasculitis / Q000188:drug therapy* / Q000276:immunology
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D007166:Immunosuppressive Agents; D018836:Inflammation Mediators